Ozempic and big pharma: Shortcut or health risk?
Shane Hewitt speaks with Tony Chapman about the growing use of Ozempic beyond diabetes treatment. Chapman questions whether pharmaceutical marketing is pushing prescription shortcuts over long-term lifestyle changes, and warns about potential health consequences. Connect with 580 CFRA Online: Subscribe to 580 CFRA: https://bit.ly/4o8AKWp Visit the website: https://www.cfra.com/ Likes us on Facebook: https://bit.ly/47YzDm4 source